Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 598

1.

Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.

de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP.

Eur Urol Oncol. 2020 Mar 20. pii: S2588-9311(20)30035-3. doi: 10.1016/j.euo.2020.02.010. [Epub ahead of print]

PMID:
32205136
2.

Novel technologies that change the diagnostic and treatment paradigm in urology: standard turbt remains the standard.

Lotan Y.

Curr Opin Urol. 2020 May;30(3):477-478. doi: 10.1097/MOU.0000000000000746. No abstract available.

PMID:
32168193
3.

A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging.

de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA.

J Urol. 2020 Feb 14:101097JU0000000000000798. doi: 10.1097/JU.0000000000000798. [Epub ahead of print]

PMID:
32074006
4.

Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.

D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF.

Urol Oncol. 2020 Feb 11. pii: S1078-1439(20)30011-9. doi: 10.1016/j.urolonc.2020.01.010. [Epub ahead of print]

PMID:
32057595
5.

Evaluation of Hematuria in a Large Public Health Care System.

Ghandour R, Freifeld Y, Singla N, Lotan Y.

Bladder Cancer. 2019;5(2):119-129. doi: 10.3233/BLC-190221. Epub 2019 Aug 16.

6.

PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy.

Yeh HC, Margulis V, Singla N, Hernandez E, Panwar V, Woldu SL, Karam JA, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Li CC, Ke HL, Li WM, Lee HY, Rapoport LM, Lotan Y, Kapur P, Shariat SF, Hsieh JT, Wu WJ.

Urol Oncol. 2019 Dec 17. pii: S1078-1439(19)30483-1. doi: 10.1016/j.urolonc.2019.11.010. [Epub ahead of print]

PMID:
31862213
7.

Correction: Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer.

Vantaku V, Donepudi SR, Ambati CR, Jin F, Putluri V, Nguyen K, Rajapakshe K, Coarfa C, Battula VL, Lotan Y, Putluri N.

Oncotarget. 2019 Nov 26;10(63):6843-6844. doi: 10.18632/oncotarget.27311. eCollection 2019 Nov 26.

8.

Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy.

Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, Kaimakliotis HZ, Gibb EA, Lotan Y.

Urol Oncol. 2019 Dec 4. pii: S1078-1439(19)30459-4. doi: 10.1016/j.urolonc.2019.11.004. [Epub ahead of print]

PMID:
31812633
9.

Non-visible haematuria for the Detection of Bladder, Upper Tract, and Kidney Cancer: An Updated Systematic Review and Meta-analysis.

Jubber I, Shariat SF, Conroy S, Tan WS, Gordon PC, Lotan Y, Messing EM, Stenzl A, Rhijn BV, Kelly JD, Catto JWF, Cumberbatch MG.

Eur Urol. 2019 Nov 29. pii: S0302-2838(19)30776-6. doi: 10.1016/j.eururo.2019.10.010. [Epub ahead of print] Review.

PMID:
31791622
10.

Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial.

Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ Jr, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, Manoharan M, Maroni P, Perrapato S, Sieber P, Trabulsi EJ, Waterhouse R, Spratt DE, Davicioni E, Lotan Y, Lin DW.

Pract Radiat Oncol. 2020 Mar - Apr;10(2):e82-e90. doi: 10.1016/j.prro.2019.09.016. Epub 2019 Nov 21.

PMID:
31761540
11.

Critical treatment choices for patients with platinum-refractory urothelial carcinoma.

Lotan Y, Meng X.

Lancet Oncol. 2020 Jan;21(1):11-13. doi: 10.1016/S1470-2045(19)30661-8. Epub 2019 Nov 18. No abstract available.

PMID:
31753728
12.

Serum MicroRNA-371a-3p Levels Predict Viable Germ Cell Tumor in Chemotherapy-naïve Patients Undergoing Retroperitoneal Lymph Node Dissection.

Lafin JT, Singla N, Woldu SL, Lotan Y, Lewis CM, Majmudar K, Savelyeva A, Kapur P, Margulis V, Strand DW, Murray MJ, Amatruda JF, Bagrodia A.

Eur Urol. 2020 Feb;77(2):290-292. doi: 10.1016/j.eururo.2019.10.005. Epub 2019 Nov 5. No abstract available.

PMID:
31699528
13.

The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.

Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC.

Urol Oncol. 2020 Jan;38(1):3.e17-3.e27. doi: 10.1016/j.urolonc.2019.09.023. Epub 2019 Oct 31.

PMID:
31676278
14.

Reply by Authors.

Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA.

J Urol. 2020 Mar;203(3):625-626. doi: 10.1097/JU.0000000000000625. Epub 2019 Oct 25. No abstract available.

PMID:
31651229
15.

Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.

de Jong JJ, Liu Y, Robertson AG, Seiler R, Groeneveld CS, van der Heijden MS, Wright JL, Douglas J, Dall'Era M, Crabb SJ, van Rhijn BWG, van Kessel KEM, Davicioni E, Castro MAA, Lotan Y, Zwarthoff EC, Black PC, Boormans JL, Gibb EA.

Genome Med. 2019 Oct 17;11(1):60. doi: 10.1186/s13073-019-0669-z.

16.

Uptake of HDL-cholesterol contributes to lipid accumulation in clear cell renal cell carcinoma.

Kim J, Thompson B, Han S, Lotan Y, McDonald JG, Ye J.

Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Dec;1864(12):158525. doi: 10.1016/j.bbalip.2019.158525. Epub 2019 Sep 9.

PMID:
31513923
17.

Erratum to "Distinct Lipidomic Landscapes Associated with Clinical Stages of Urothelial Cancer of the Bladder" [Eur Urol Focus 2018;4:907-915].

Piyarathna DWB, Rajendiran TM, Putluri V, Vantaku V, Soni T, von Rundstedt FC, Donepudi SR, Jin F, Maity S, Ambati CR, Dong J, Gödde D, Roth S, Störkel S, Degener S, Michailidis G, Lerner SP, Pennathur S, Lotan Y, Coarfa C, Sreekumar A, Putluri N.

Eur Urol Focus. 2019 Sep;5(5):920. doi: 10.1016/j.euf.2019.08.010. Epub 2019 Aug 30. No abstract available.

PMID:
31474581
18.

Current advances in BCG-unresponsive non-muscle invasive bladder cancer.

Tse J, Singla N, Ghandour R, Lotan Y, Margulis V.

Expert Opin Investig Drugs. 2019 Sep;28(9):757-770. doi: 10.1080/13543784.2019.1655730. Epub 2019 Aug 15. Review.

PMID:
31412742
19.

Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy.

Freifeld Y, Woldu SL, Singla N, Clinton T, Bagrodia A, Hutchinson R, Lotan Y, Margulis V.

Eur Urol Oncol. 2019 Nov;2(6):691-698. doi: 10.1016/j.euo.2018.10.005. Epub 2018 Nov 16.

PMID:
31411983
20.

Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes.

Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan WS, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz PI, Rouprêt M, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Lotan Y, Sooriakumaran P, Shariat SF.

J Clin Med. 2019 Aug 9;8(8). pii: E1192. doi: 10.3390/jcm8081192.

21.

Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression.

Vantaku V, Putluri V, Bader DA, Maity S, Ma J, Arnold JM, Rajapakshe K, Donepudi SR, von Rundstedt FC, Devarakonda V, Dubrulle J, Karanam B, McGuire SE, Stossi F, Jain AK, Coarfa C, Cao Q, Sikora AG, Villanueva H, Kavuri SM, Lotan Y, Sreekumar A, Putluri N.

Oncogene. 2019 Aug 5. doi: 10.1038/s41388-019-0902-7. [Epub ahead of print]

PMID:
31383940
22.

Preoperative predictive model and nomogram for disease recurrence following radical nephroureterectomy for high grade upper tract urothelial carcinoma.

Freifeld Y, Ghandour R, Singla N, Woldu S, Clinton T, Kulangara R, Bagrodia A, Matin SF, Petros FG, Raman JD, Robyak H, Yan J, Zhu H, Rapoport L, Lotan Y, Margulis V.

Urol Oncol. 2019 Oct;37(10):758-764. doi: 10.1016/j.urolonc.2019.06.009. Epub 2019 Aug 2.

PMID:
31378586
23.

Treatment Options and Outcomes in Nonmetastatic Muscle Invasive Bladder Cancer.

Ghandour R, Singla N, Lotan Y.

Trends Cancer. 2019 Jul;5(7):426-439. doi: 10.1016/j.trecan.2019.05.011. Epub 2019 Jun 22. Review.

PMID:
31311657
24.

DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism.

Vantaku V, Amara CS, Piyarathna DWB, Donepudi SR, Ambati CR, Putluri V, Tang W, Rajapakshe K, Estecio MR, Terris MK, Castro PD, Ittmann MM, Williams SB, Lerner SP, Sreekumar A, Bollag R, Coarfa C, Kornberg MD, Lotan Y, Ambs S, Putluri N.

Carcinogenesis. 2019 Nov 25;40(11):1332-1340. doi: 10.1093/carcin/bgz128.

PMID:
31284295
25.

Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate.

Costa DN, Goldberg K, Leon AD, Lotan Y, Xi Y, Aziz M, Freifeld Y, Margulis V, Raj G, Roehrborn CG, Hornberger B, Desai N, Bagrodia A, Francis F, Pedrosa I, Cadeddu JA.

Eur Urol Oncol. 2019 Jul;2(4):397-404. doi: 10.1016/j.euo.2018.08.022. Epub 2018 Sep 20.

PMID:
31277776
26.

Nationwide Patterns of Care for Stage II Nonseminomatous Germ Cell Tumor of the Testicle.

Ghandour R, Ashbrook C, Freifeld Y, Singla N, El-Asmar JM, Lotan Y, Margulis V, Eggener S, Woldu S, Bagrodia A.

Eur Urol Oncol. 2019 Jul 1. pii: S2588-9311(19)30082-3. doi: 10.1016/j.euo.2019.06.007. [Epub ahead of print]

PMID:
31272940
27.

Reduction of Pain during Flexible Cystoscopy: A Systematic Review and Meta-Analysis.

Raskolnikov D, Brown B, Holt SK, Ball AL, Lotan Y, Strope S, Schroeck F, Ullman R, Lipman R, Smith AB, Gore JL.

J Urol. 2019 Dec;202(6):1136-1142. doi: 10.1097/JU.0000000000000399. Epub 2019 Jun 20.

PMID:
31219763
28.

Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial.

Lotan Y, Inman BA, Davis LG, Kassouf W, Messing E, Daneshmand S, Canter D, Marble HT, Joseph AM, Jewell S, Boorjian SA.

J Urol. 2019 Nov;202(5):920-926. doi: 10.1097/JU.0000000000000355. Epub 2019 Oct 9.

PMID:
31120373
29.

Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.

Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y.

Eur Urol. 2019 Aug;76(2):238-243. doi: 10.1016/j.eururo.2019.04.035. Epub 2019 May 16.

30.

Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review.

Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC.

Eur Urol Oncol. 2018 Aug;1(3):223-230. doi: 10.1016/j.euo.2018.04.010. Epub 2018 May 15. Review.

PMID:
31102625
31.

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA.

Eur Urol. 2019 Aug;76(2):200-206. doi: 10.1016/j.eururo.2019.04.036. Epub 2019 May 12.

PMID:
31092337
32.

Practice Patterns and Impact of Postchemotherapy Retroperitoneal Lymph Node Dissection on Testicular Cancer Outcomes.

Woldu SL, Moore JA, Ci B, Freifeld Y, Clinton TN, Aydin AM, Singla N, Laura-Maria K, Hutchinson RC, Amatruda JF, Sagalowsky A, Lotan Y, Arriaga Y, Margulis V, Xie Y, Bagrodia A.

Eur Urol Oncol. 2018 Aug;1(3):242-251. doi: 10.1016/j.euo.2018.04.005. Epub 2018 Jun 6.

33.

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.

Nat Rev Urol. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4. Review.

PMID:
31019310
34.

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC.

Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5.

PMID:
30952638
35.

Progress toward a Nordic standard for the investigation of hematuria: 2019.

Lotan Y.

Scand J Urol. 2019 Feb;53(1):8. doi: 10.1080/21681805.2019.1594581. Epub 2019 Apr 2. No abstract available.

PMID:
30935284
36.

Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.

Owyong M, Lotan Y, Kapur P, Panwar V, McKenzie T, Lee TK, Zi X, Martin JW, Mosbah A, Abol-Enein H, Ghoneim M, Youssef RF.

Urol Oncol. 2019 Jul;37(7):478-484. doi: 10.1016/j.urolonc.2019.02.017. Epub 2019 Mar 23.

PMID:
30910351
37.

Predicting recurrence in patients with localised renal cell carcinoma after nephrectomy.

Lotan Y, Margulis V.

Lancet Oncol. 2019 Apr;20(4):473-475. doi: 10.1016/S1470-2045(19)30024-5. Epub 2019 Mar 14. No abstract available.

PMID:
30880069
38.

Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer.

Vantaku V, Dong J, Ambati CR, Perera D, Donepudi SR, Amara CS, Putluri V, Ravi SS, Robertson MJ, Piyarathna DWB, Villanueva M, von Rundstedt FC, Karanam B, Ballester LY, Terris MK, Bollag RJ, Lerner SP, Apolo AB, Villanueva H, Lee M, Sikora AG, Lotan Y, Sreekumar A, Coarfa C, Putluri N.

Clin Cancer Res. 2019 Jun 15;25(12):3689-3701. doi: 10.1158/1078-0432.CCR-18-1515. Epub 2019 Mar 7.

PMID:
30846479
39.

Delivery of Bottled Water to Women With Recurrent Urinary Tract Infections: Why in Bulgaria?-Reply.

Hooton TM, Vecchio M, Lotan Y.

JAMA Intern Med. 2019 Mar 1;179(3):449. doi: 10.1001/jamainternmed.2018.7977. No abstract available.

PMID:
30830193
40.

Clinical Validation of IsoPSA™, a Single Parameter, Structure Based Assay for Improved Detection of High Grade Prostate Cancer.

Stovsky M, Klein EA, Chait A, Manickam K, Stephenson AJ, Wagner M, Dineen M, Lotan Y, Partin A, Baniel J, Kestranek A, Gawande P, Boris Zaslavsky.

J Urol. 2019 Jun;201(6):1115-1120. doi: 10.1097/JU.0000000000000185.

PMID:
30810464
41.

Molecular Predictors of Complete Response Following Neoadjuvant Chemotherapy in Urothelial Carcinoma of the Bladder and Upper Tracts.

Tse J, Ghandour R, Singla N, Lotan Y.

Int J Mol Sci. 2019 Feb 13;20(4). pii: E793. doi: 10.3390/ijms20040793. Review.

42.

Recent advances in the metabolomic study of bladder cancer.

Amara CS, Vantaku V, Lotan Y, Putluri N.

Expert Rev Proteomics. 2019 Apr;16(4):315-324. doi: 10.1080/14789450.2019.1583105. Epub 2019 Feb 26.

43.

Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.

Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM.

World J Urol. 2019 Nov;37(11):2419-2427. doi: 10.1007/s00345-019-02678-x. Epub 2019 Feb 13.

PMID:
30759271
44.

Diagnostic Performance of Prospectively Assigned Likert Scale Scores to Determine Extraprostatic Extension and Seminal Vesicle Invasion With Multiparametric MRI of the Prostate.

Freifeld Y, Diaz de Leon A, Xi Y, Pedrosa I, Roehrborn CG, Lotan Y, Francis F, Costa DN.

AJR Am J Roentgenol. 2019 Mar;212(3):576-581. doi: 10.2214/AJR.18.20320. Epub 2018 Dec 27.

PMID:
30589381
45.

Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.

Valenberg FJPV, Hiar AM, Wallace E, Bridge JA, Mayne DJ, Beqaj S, Sexton WJ, Lotan Y, Weizer AZ, Jansz GK, Stenzl A, Danella JF, Shepard B, Cline KJ, Williams MB, Montgomery S, David RD, Harris R, Klein EW, Bradford TJ, Wolk FN, Westenfelder KR, Trainer AF, Richardson TA, Egerdie RB, Goldfarb B, Zadra JA, Ge S, Zhao S, Simon IM, Campbell SA, Rhees B, Bates MP, Higuchi RG, Witjes JA.

Eur Urol. 2019 May;75(5):853-860. doi: 10.1016/j.eururo.2018.11.055. Epub 2018 Dec 12.

PMID:
30553612
46.

Optimal sampling scheme in men with abnormal multiparametric MRI undergoing MRI-TRUS fusion prostate biopsy.

Freifeld Y, Xi Y, Passoni N, Woldu S, Hornberger B, Goldberg K, Bagrodia A, Raj G, Margulis V, Cadeddu JA, Lotan Y, Francis F, Pedrosa I, G Roehrborn C, Costa DN.

Urol Oncol. 2019 Jan;37(1):57-62. doi: 10.1016/j.urolonc.2018.10.009. Epub 2018 Nov 13.

PMID:
30446460
47.

A Festschrift in Honor of Edward M. Messing, MD, FACS.

Joseph JV, Brasacchio R, Fung C, Reeder J, Bylund K, Sahasrabudhe D, Yeh SY, Ghazi A, Fultz P, Rubens D, Wu G, Singer E, Schwarz E, Mohile S, Mohler J, Theodorescu D, Lee YF, Okunieff P, McConkey D, Rashid H, Chang C, Fradet Y, Guru K, Kukreja J, Sufrin G, Lotan Y, Bailey H, Noyes K, Schwartz S, Rideout K, Bratslavsky G, Campbell SC, Derweesh I, Abrahamsson PA, Soloway M, Gomella L, Golijanin D, Svatek R, Frye T, Lerner S, Palapattu G, Wilding G, Droller M, Trump D.

Bladder Cancer. 2018 Oct 3;4(Suppl 1):S1-S43. doi: 10.3233/BLC-189037. No abstract available.

48.

Validating the predictors of outcomes after radical cystectomy for bladder cancer.

Woldu SL, Sanli O, Clinton TN, Lotan Y.

Cancer. 2019 Jan 15;125(2):223-231. doi: 10.1002/cncr.31799. Epub 2018 Oct 6.

49.

Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial.

Hooton TM, Vecchio M, Iroz A, Tack I, Dornic Q, Seksek I, Lotan Y.

JAMA Intern Med. 2018 Nov 1;178(11):1509-1515. doi: 10.1001/jamainternmed.2018.4204.

50.

Effect of blue-light cystoscopy on contemporary performance of urine cytology.

Freifeld Y, Lotan Y.

BJU Int. 2019 Aug;124(2):251-257. doi: 10.1111/bju.14574. Epub 2018 Oct 21.

PMID:
30281893

Supplemental Content

Support Center